Fast Track Group FTRK 深 滬
等待開盤 08-14 09:30:00 美东时间
0.4395
+0.010
+2.21%
華盛通- 最 高0.44
- 今 開0.42
- 成交量 54.90万股
- 最 低 0.3898
- 昨 收 0.43
- 總市值 933.94万
- 52周最高 9.69
- 市盈率 靜 --
- 換手率 2.58%
- 52周最低 0.3898
- 委 比 76.00%
- 總股本 2125.00万
- 歷史最高 9.69
- 量 比 1.07
- 振 幅 11.67%
- 歷史最低 0.3898
- 每 手 1
- 風險率 2.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate
Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's disease.
08-13 23:15
12 Communication Services Stocks Moving In Monday's After-Market Session
Gainers WideOpenWest (NYSE:WOW) shares rose 48.2% to $5.01 during Monday's aft...
08-12 05:06
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
SAN DIEGO, Aug. 11, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Corporation" or the "Company"), a clinical-stage immunotherapy company devel...
08-12 04:55
Azitra, Inc. Announces Reverse Stock Split
Common Stock Will Begin Trading on a Split-Adjusted Basis on August 21, 2025 BRANFORD, Conn., Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceut...
08-12 04:15
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
Received clearance to proceed with pivotal trial of amezalpat combination thera...
08-12 04:12
【国盛医药】：减肥PRO未来技术路线之争？各公司整体进展如何？【周专题&周观点】【总第409期】
（来源：国医盛视） 一、医药核心观点 当周（8.4-8.8）回顾与周专题： 当周（8.4-8.8）申万医药指数环比-0.84%，跑输沪深300指...
08-10 10:32
一周医药速览（08.04-08.08）
百济神州Q2总收入提高42%至13亿美元，百悦泽®在欧洲销售额增长85% 百济神州公布2025年第二季度财务业绩。披露公司2025年第二季度总收入为13亿美元...
08-08 15:33
Lantern Pharma's Starlight Therapeutics Receives FDA Clearance Its IND For Phase Ib/2a Glioblastoma Multiforme Trial
Novel combination therapy with STAR-001 targets the most aggressive and deadliest forms of brain cancer at first progressionGBM represents an annual market opportunity of $3 to $5 billion USD with an accelerating number
08-06 20:32
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
NetworkNewsWire Editorial Coverage NEW YORK, Aug. 6, 2025 /PRNewswire/ -- As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, partic...
08-06 20:30
迪哲医药：在研产品DZD8586获美国FDA快速通道认定
8月6日，迪哲医药（688192）公告称，近日，公司在研产品DZD8586获美国食品药品监督管理局授予“快速通道认定”（“Fast Track Designation”）用于既往接受过至少两线治疗（包括布鲁顿氏酪氨酸激酶（BTK）抑制剂和BCL-2抑制剂）的复发难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）。
08-06 19:15
